At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
AKST4290 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
In Brief
A Phase 2 clinical trial evaluating AKST4290 and Placebo for Parkinson Disease. Completed, enrolled 110 participants across 22 sites in 5 countries.
Detailed Summary
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesEstonia, Germany, Poland, Slovakia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedApr 2020
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedApr 30, 2020
Enrollment StartJan 16, 2020
Primary CompletionFeb 11, 2021
Study CompletionMar 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.2 years ago
Interventions
AKST4290drug
Oral AKST4290
Placebodrug
Oral Placebo